Welcome to our dedicated page for Nuvation Bio SEC filings (Ticker: NUVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing packed with clinical jargon, trial data, and cash-runway footnotes can feel like decoding another language. Nuvation Bio’s disclosures are no exception—every 10-K details R&D for its BD2-selective BET inhibitor, and each 8-K can signal a pivotal study update. That’s why investors searching for “Nuvation Bio SEC filings explained simply” come here first.
Stock Titan’s AI bridges the gap between dense oncology science and clear insight. Whether you need the latest “Nuvation Bio quarterly earnings report 10-Q filing” or want “Nuvation Bio 8-K material events explained,” our platform extracts trial timelines, cash burn, and milestone payments in seconds. Real-time alerts flag “Nuvation Bio Form 4 insider transactions real-time,” so you’ll never miss when executives file “Nuvation Bio insider trading Form 4 transactions.”
Use the filings hub to:
- Track pipeline progress through 8-Ks and see how new data affect valuation.
- Compare R&D outlays across quarters with AI summaries of each 10-Q.
- Monitor “Nuvation Bio executive stock transactions Form 4” for alignment of leadership incentives.
- Review the “Nuvation Bio proxy statement executive compensation” without wading through tables.
From a “Nuvation Bio annual report 10-K simplified” breakdown to a concise “Nuvation Bio earnings report filing analysis,” every document is updated the moment it hits EDGAR. Still puzzling over footnotes? Try “understanding Nuvation Bio SEC documents with AI” and let Stock Titan translate 200-page filings into the metrics that matter.
Insider Trading Alert: Stacy Markel, Chief People Officer of Nuvation Bio (NUVB), purchased 10,000 shares of Class A Common Stock on June 18, 2025, at a price of $1.71 per share, representing a total investment of $17,100.
Following this transaction, Markel now holds 29,591 shares directly, which includes 3,000 shares previously acquired through the company's 2021 Employee Stock Purchase Plan on May 19, 2025. The purchase was executed as a direct ownership transaction.
This insider buying activity by a key executive officer could signal confidence in the company's future prospects. The transaction was reported via Form 4 filing and executed in compliance with SEC regulations, with the filing submitted through an attorney-in-fact, Stephen Dang.
Nuvation Bio CFO Philippe Sauvage reported two insider purchase transactions of Class A Common Stock:
- On June 16, 2025: Acquired 3,300 shares at $1.835 per share
- On June 17, 2025: Acquired 4,000 shares at $1.79 per share
Following these transactions, Sauvage's direct ownership increased to 9,902 shares. The filing notes that his holdings include 2,602 shares previously acquired through the company's 2021 Employee Stock Purchase Plan on May 19, 2025. These insider purchases by the CFO, totaling 7,300 shares over two consecutive days, may signal management's confidence in the company's valuation and future prospects.
Insider Purchase Alert: Colleen Sjogren, Chief Commercial Officer of Nuvation Bio (NUVB), has acquired 50,000 shares of Class A Common Stock on June 16, 2025, at a weighted average price of $1.807 per share, representing a total investment of approximately $90,350.
Following this transaction, Sjogren now beneficially owns 81,000 shares directly, which includes 3,000 shares previously acquired through the company's 2021 Employee Stock Purchase Plan on May 19, 2025. The purchase was executed in multiple transactions with prices ranging from $1.795 to $1.82 per share.
This insider purchase by a senior executive could signal confidence in the company's future prospects. The transaction was reported via Form 4 filing and executed in compliance with securities regulations, with the filing submitted through an attorney-in-fact on June 18, 2025.
Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio (NUVB), reported significant insider purchases on June 16, 2025. The transactions involved:
- First purchase: 26,000 shares of Class A Common Stock at $1.79 per share
- Second purchase: 24,000 shares of Class A Common Stock at $1.80 per share
Following these transactions, Wentworth directly owns a total of 50,000 shares of Class A Common Stock. The insider's substantial purchase of shares, totaling approximately $89,740, could signal confidence in the company's future prospects. The Form 4 was filed through an attorney-in-fact, Stephen Dang, on June 18, 2025.
David Hung, President, CEO, Director, and 10% owner of Nuvation Bio (NUVB), has made a significant insider purchase of 500,000 shares of Class A Common Stock on June 16, 2025. The shares were acquired at a weighted-average price of $1.787 per share, with purchase prices ranging from $1.64 to $1.88.
Following this transaction, Hung's direct ownership increased to 59,281,054 shares. The substantial purchase by the company's chief executive, representing an investment of approximately $893,500, may signal management's confidence in the company's future prospects.
Key transaction details:
- Transaction type: Direct purchase of common stock
- Total transaction value: ~$893,500
- Filing was signed by Stephen Dang as attorney-in-fact
- No derivative securities were involved in this transaction
FAQ
What is the current stock price of Nuvation Bio (NUVB)?
What is the market cap of Nuvation Bio (NUVB)?
What is the core focus of Nuvation Bio Inc?
How does Nuvation Bio Inc approach cancer treatment?
What makes Nuvation Bio's therapeutic candidates unique?
Who founded Nuvation Bio Inc and why is this significant?
What technology platforms does the company employ?
How does Nuvation Bio differentiate itself in the oncology market?
In what stages are Nuvation Bio's products currently?
What benefits does Nuvation Bio’s research model offer?
